A systematic review and meta-analysis compared clinical and patient-reported outcomes between subcapsular and total orchiectomy in patients with advanced prostate cancer.
Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy ...
Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients. The FDA has approved darolutamide (Nubeqa; Bayer ...
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their ...
July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results